New class of drug leads to 30% reduced risk of death for bladder cancer patients
E-Mail A new type of drug that helps target chemotherapy directly to cancer cells has been found to significantly increase survival of patients with the most common form of bladder cancer, according to results from a phase III clinical trial led in the UK by Queen Mary University of London and Barts Health NHS Trust. The results are published in the New England Journal of Medicine and were presented at the 2021 American Society of Clinical Oncology's Genitourinary Cancers Symposium. Urothelial cancer is the most common type of bladder cancer (90 percent of cases) and can also be found in ...